Omnicell (OMCL) to Release Quarterly Earnings on Thursday

Omnicell (NASDAQ:OMCL - Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Omnicell to post earnings of $0.57 per share and revenue of $297.88 million for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Omnicell Trading Up 1.4 %

Shares of NASDAQ:OMCL traded up $0.62 during midday trading on Thursday, hitting $45.31. The company had a trading volume of 221,342 shares, compared to its average volume of 316,565. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The firm has a fifty day simple moving average of $44.68 and a 200 day simple moving average of $42.64. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -116.18, a PEG ratio of 29.73 and a beta of 0.78.

Analyst Ratings Changes

A number of brokerages have recently commented on OMCL. JPMorgan Chase & Co. upped their price target on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Craig Hallum upped their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Bank of America reduced their price target on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Benchmark restated a "buy" rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Finally, Wells Fargo & Company dropped their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $50.00.

Insider Buying and Selling

In other news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.64% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.